These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. Parsanezhad ME; Azmoon M; Alborzi S; Rajaeefard A; Zarei A; Kazerooni T; Frank V; Schmidt EH Fertil Steril; 2010 Jan; 93(1):192-8. PubMed ID: 19135657 [TBL] [Abstract][Full Text] [Related]
3. Action of aromatase inhibitor for treatment of uterine leiomyoma in perimenopausal patients. Hilário SG; Bozzini N; Borsari R; Baracat EC Fertil Steril; 2009 Jan; 91(1):240-3. PubMed ID: 18249392 [TBL] [Abstract][Full Text] [Related]
4. Goserelin acetate 10.8 mg plus iron versus iron monotherapy prior to surgery in premenopausal women with iron-deficiency anemia due to uterine leiomyomas: results from a Phase III, randomized, multicenter, double-blind, controlled trial. Muneyyirci-Delale O; Richard-Davis G; Morris T; Armstrong J Clin Ther; 2007 Aug; 29(8):1682-91. PubMed ID: 17919549 [TBL] [Abstract][Full Text] [Related]
5. Gonadotrophin-releasing hormone and magnetic-resonance-guided ultrasound surgery for uterine leiomyomata. Smart OC; Hindley JT; Regan L; Gedroyc WG Obstet Gynecol; 2006 Jul; 108(1):49-54. PubMed ID: 16816055 [TBL] [Abstract][Full Text] [Related]
6. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas. Palomba S; Orio F; Russo T; Falbo A; Cascella T; Doldo P; Nappi C; Lombardi G; Mastrantonio P; Zullo F Hum Reprod; 2004 Jun; 19(6):1308-14. PubMed ID: 15117890 [TBL] [Abstract][Full Text] [Related]
7. Low-dose mifepristone in treatment of uterine leiomyoma: a randomised double-blind placebo-controlled clinical trial. Bagaria M; Suneja A; Vaid NB; Guleria K; Mishra K Aust N Z J Obstet Gynaecol; 2009 Feb; 49(1):77-83. PubMed ID: 19281585 [TBL] [Abstract][Full Text] [Related]
8. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Williams AR; Critchley HO; Osei J; Ingamells S; Cameron IT; Han C; Chwalisz K Hum Reprod; 2007 Jun; 22(6):1696-704. PubMed ID: 17339234 [TBL] [Abstract][Full Text] [Related]
9. Open-label study of ultra low-dose mifepristone for the treatment of uterine leiomyomata. Eisinger SH; Fiscella J; Bonfiglio T; Meldrum S; Fiscella K Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):215-8. PubMed ID: 19586708 [TBL] [Abstract][Full Text] [Related]
10. Percutaneous image-guided radiofrequency thermal ablation for large symptomatic uterine leiomyomata after uterine artery embolization: a feasibility and safety study. Kim HS; Tsai J; Jacobs MA; Kamel IR J Vasc Interv Radiol; 2007 Jan; 18(1 Pt 1):41-8. PubMed ID: 17296703 [TBL] [Abstract][Full Text] [Related]
11. Sustained relief of leiomyoma symptoms by using focused ultrasound surgery. Stewart EA; Gostout B; Rabinovici J; Kim HS; Regan L; Tempany CM Obstet Gynecol; 2007 Aug; 110(2 Pt 1):279-87. PubMed ID: 17666601 [TBL] [Abstract][Full Text] [Related]
12. Tibolone reverses the cognitive effects caused by leuprolide acetate administration, improving mood and quality of life in patients with symptomatic uterine leiomyomas. Palomba S; Orio F; Falbo A; Oppedisano R; Tolino A; Zullo F Fertil Steril; 2008 Jul; 90(1):165-73. PubMed ID: 18001721 [TBL] [Abstract][Full Text] [Related]
13. [Treatment of uterine leiomyoma with depot leuprorelin acetate (Enantone-Gyn monthly depot). Effect on leiomyoma volume and operability. German Leuprorelin Study Group]. Stolz W; Pfützenreuter N Zentralbl Gynakol; 1997; 119(10):468-75. PubMed ID: 9432825 [TBL] [Abstract][Full Text] [Related]
14. A placebo-controlled trial of a depot gonadotropin-releasing hormone analogue (leuprolide) in the treatment of uterine leiomyomata. Schlaff WD; Zerhouni EA; Huth JA; Chen J; Damewood MD; Rock JA Obstet Gynecol; 1989 Dec; 74(6):856-62. PubMed ID: 2511532 [TBL] [Abstract][Full Text] [Related]
15. A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Chwalisz K; Larsen L; Mattia-Goldberg C; Edmonds A; Elger W; Winkel CA Fertil Steril; 2007 Jun; 87(6):1399-412. PubMed ID: 17307170 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of leuprorelin acetate depot in symptomatic fibromatous uteri: the Italian Multicentre Trial. Serra GB; Panetta V; Colosimo M; Romanini C; Lafuenti GB; Garcea N; Votano S; Agatensi L Clin Ther; 1992; 14 Suppl A():57-73. PubMed ID: 1606594 [TBL] [Abstract][Full Text] [Related]
17. Role of the aromatase inhibitor letrozole in the management of uterine leiomyomas in premenopausal women. Duhan N; Madaan S; Sen J Eur J Obstet Gynecol Reprod Biol; 2013 Dec; 171(2):329-32. PubMed ID: 24103533 [TBL] [Abstract][Full Text] [Related]
18. The effect of levonorgestrel intrauterine system on uterine myomas: a 1-year follow-up study. Gunes M; Ozdegirmenci O; Kayikcioglu F; Haberal A; Kaplan M J Minim Invasive Gynecol; 2008; 15(6):735-8. PubMed ID: 18971138 [TBL] [Abstract][Full Text] [Related]